Taking place at the Wolfson Lecture Theatre, Churchill College (Storey's Way, Cambridge CB3 0DS) on Monday January 18th (7pm for 7.30 pm), Dr Pangalos will talk about 'The challenge and excitement of discovering new medicine.'
He says: "At AstraZeneca, our purpose is to push the boundaries of science to deliver life-changing medicines. The future treatment for many of today’s diseases lies in discovering new biology, and understanding and challenging scientific hypotheses, to develop novel therapies.
"The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue - and with it new drug discovery challenges. By combining new technologies with medical understanding, we are making progress in our ability to define and deliver novel treatments for a variety of complex diseases.
"We also recognise that to be successful we need to work in partnership. Our teams continue to find innovative ways of collaborating with the best academic and industrial partners."
Mene Pangalos, PhD is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit. A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s small molecule discovery research and early development activities.
As one of AstraZeneca’s leading scientists, Mene has published more than 140 peer-reviewed articles in scientific journals and has served as an editor of books and journals in neuroscience.
Find out more and sign up here.
_____________________________________________
AstraZeneca scientist talks about the challenge and excitement of discovering new medicine
12 January 2016
Dr Menelas Pangalos, Executive Vice-President of AstraZeneca, will be the key speaker at a Cambridge Network event next week, held jointly with Cambridge Society for the Application of Research (CSAR) and the Cambridge Philosophical Society.